JTC Employer Solutions Trustee Ltd Sells 2,168,878 Shares of Haleon plc (NYSE:HLN)

JTC Employer Solutions Trustee Ltd trimmed its position in Haleon plc (NYSE:HLN) by 85.2% during the first quarter, HoldingsChannel.com reports. The firm owned 376,834 shares of the company’s stock after selling 2,168,878 shares during the quarter. JTC Employer Solutions Trustee Ltd’s holdings in Haleon were worth $3,216,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of the company. Hexagon Capital Partners LLC boosted its position in Haleon by 107.3% during the fourth quarter. Hexagon Capital Partners LLC now owns 4,236 shares of the company’s stock valued at $35,000 after purchasing an additional 2,193 shares during the last quarter. Pinnacle Bancorp Inc. boosted its position in Haleon by 853.4% during the fourth quarter. Pinnacle Bancorp Inc. now owns 4,767 shares of the company’s stock valued at $39,000 after purchasing an additional 4,267 shares during the last quarter. Allspring Global Investments Holdings LLC acquired a new position in Haleon during the first quarter valued at approximately $43,000. Tower Research Capital LLC TRC boosted its position in Haleon by 146.8% during the fourth quarter. Tower Research Capital LLC TRC now owns 5,398 shares of the company’s stock valued at $44,000 after purchasing an additional 3,211 shares during the last quarter. Finally, SRS Capital Advisors Inc. boosted its position in Haleon by 456.4% during the fourth quarter. SRS Capital Advisors Inc. now owns 5,458 shares of the company’s stock valued at $45,000 after purchasing an additional 4,477 shares during the last quarter. 6.67% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

HLN has been the subject of several recent research reports. HSBC initiated coverage on Haleon in a research report on Wednesday, April 17th. They set a “buy” rating for the company. Berenberg Bank initiated coverage on Haleon in a research report on Wednesday, June 5th. They set a “buy” rating for the company. Finally, Argus reissued a “buy” rating on shares of Haleon in a research report on Tuesday, March 26th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy”.

Haleon Stock Performance

Shares of HLN traded up $0.12 during mid-day trading on Wednesday, reaching $8.46. The company’s stock had a trading volume of 1,761,769 shares, compared to its average volume of 5,338,670. Haleon plc has a 1-year low of $7.70 and a 1-year high of $8.96. The stock has a market cap of $38.61 billion, a P/E ratio of 28.18, a PEG ratio of 2.19 and a beta of 0.25. The business has a 50-day simple moving average of $8.41 and a two-hundred day simple moving average of $8.35. The company has a current ratio of 1.04, a quick ratio of 0.73 and a debt-to-equity ratio of 0.53.

Haleon (NYSE:HLN) last announced its earnings results on Wednesday, May 1st. The company reported $0.12 earnings per share for the quarter, topping analysts’ consensus estimates of $0.11 by $0.01. The company had revenue of $3.70 billion for the quarter, compared to analyst estimates of $3.71 billion. Haleon had a return on equity of 13.17% and a net margin of 9.68%. As a group, equities research analysts anticipate that Haleon plc will post 0.46 earnings per share for the current fiscal year.

Haleon Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.